Please login to the form below

Not currently logged in
Email:
Password:

antibodies

This page shows the latest antibodies news and features for those working in and with pharma, biotech and healthcare.

Biogen loses another pipeline drug to toxicity concerns

Biogen loses another pipeline drug to toxicity concerns

The decision – announced in an  update posted on ClinicalTrials.gov – was taken because of safety concerns with the antibody drug, a humanised monoclonal antibody designed to disrupt alpha V beta 6

Latest news

More from news
Approximately 19 fully matching, plus 958 partially matching documents found.

Latest Intelligence

  • Biotech profile: Tom Evans, CEO, Vaccitech.

    This is because they induce antibodies against constantly evolving, surface antigens of the virus, so we are always playing catch up. ... It has been shown to boost human memory T-cell responses, rather than antibodies, to viral proteins that are highly

  • Orphan drugs and breakthrough therapies drive Cortellis Drugs to Watch 2019 Orphan drugs and breakthrough therapies drive Cortellis Drugs to Watch 2019

    It is a next- generation follow-on to Soliris, Alexion’s current PNH blockbuster – also a humanised monoclonal antibody – with more convenient dosing. ... Developed by Boehringer Ingelheim and AbbVie, Skyrizi is a monoclonal antibody that inhibits

  • Where next in Alzheimer’s disease R&D? Where next in Alzheimer’s disease R&D?

    The drugs include antibodies that capture tau as it spreads between cells and small molecules designed to enter cells and inhibit tau aggregation. ... AbbVie is testing its anti-tau antibody ABBV-8E12 in a phase 2 trial, while Biogen has links to two

  • Cell and gene therapy Cell and gene therapy

    Also, as Sinclair points out, strategies like process scale-up that have been used to reduce the cost of making a monoclonal antibody to $50-200 per dose cannot really be

  • Drug launches to watch in 2019 Drug launches to watch in 2019

    Takhzyro is the first antibody to be approved for HAE in a market of a handful of existing treatments, including Shire’s three existing products, Cinryze, Firazyr and Kalbitor), that collectively

More from intelligence
Approximately 1 fully matching, plus 104 partially matching documents found.

Latest appointments

More from appointments
Approximately 1 fully matching, plus 33 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 19 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Atlantis Healthcare

Atlantis Healthcare is a global leader in optimising patient self-management. Established in 1996, we design, develop and implement scalable solutions...

Latest intelligence

Report: Customer experience, shaping digital healthcare
In this issue of ‘Perspective’ we speak with industry experts to learn about the world of digital healthcare, and how pharma is beginning to utilise these modern technologies to enhance...
Biomarker
Encouraging signs in biomarker R&D
The cancer immunotherapy firms ramping-up biomarker R&D...
Programmatic methodology and why you should be using it
What is it? How does it work? Why is everyone talking about it? By Richard Webb - Associate Director...

Infographics